Q&A: Fu­ji­film Diosynth CEO Mar­tin Mee­son says com­pa­ny is in 'growth mod­e'

Fu­ji­film Diosynth had a busy 2022, in­vest­ing more than $1 bil­lion in­to its man­u­fac­tur­ing sites while ex­pand­ing its glob­al foot­print.

The com­pa­ny is a con­tract man­u­fac­tur­er of bi­o­log­ics, in­clud­ing mon­o­clon­al an­ti­bod­ies, vac­cines and gene ther­a­pies, among oth­ers. Over the last year, it broke ground on ex­pan­sions in the UK, Den­mark and Texas, and con­tin­ued to hire new staffers at its lo­ca­tion in Hol­ly Springs, NC. CEO Mar­tin Mee­son sat down with End­points News to dis­cuss chal­lenges, com­pe­ti­tion and con­struc­tion in the new year. This in­ter­view has been edit­ed for length and clar­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER